Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 389, Issue 6, Pages 514-526
Publisher
Massachusetts Medical Society
Online
2023-06-27
DOI
10.1056/nejmoa2301972
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
- (2023) Ania M. Jastreboff et al. Annual Review of Medicine
- Semaglutide in Obesity: Unmet Needs in Men
- (2023) Mojca Jensterle et al. Diabetes Therapy
- The molecular pharmacology of glucagon agonists in diabetes and obesity
- (2023) Aaron Novikoff et al. PEPTIDES
- Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
- (2022) Ellen Conceição-Furber et al. Frontiers in Endocrinology
- Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
- (2022) Elpiniki Rentzeperi et al. Journal of Personalized Medicine
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shifting Tides Offer New Hope For Obesity
- (2022) Clifford J. Rosen et al. NEW ENGLAND JOURNAL OF MEDICINE
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
- (2022) Tamer Coskun et al. Cell Metabolism
- LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
- (2022) Shweta Urva et al. LANCET
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- What Is Weight Loss After Bariatric Surgery Expressed in Percentage Total Weight Loss (%TWL)? A Systematic Review
- (2021) Anne-Sophie van Rijswijk et al. OBESITY SURGERY
- Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
- (2021) Ali Aminian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Treating the Chronic Disease of Obesity
- (2021) Mona Gossmann et al. MEDICAL CLINICS OF NORTH AMERICA
- SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design
- (2020) Donna H. Ryan et al. AMERICAN HEART JOURNAL
- Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
- (2019) Stefano Spolitu et al. CIRCULATION RESEARCH
- Glucagon Regulation of Energy Expenditure
- (2019) Maximilian Kleinert et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Does glucagon have a positive inotropic effect in the human heart?
- (2018) Jesus Hernández-Cascales Cardiovascular Diabetology
- The Physical Activity Guidelines for Americans
- (2018) Katrina L. Piercy et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now